Extended dosing intervals of ixekizumab for psoriasis: A single-center, uncontrolled, prospective study

J Am Acad Dermatol. 2022 Jun;86(6):1348-1350. doi: 10.1016/j.jaad.2021.04.093. Epub 2021 May 5.

Authors

Li-Ran Ye¹, Bing-Xi Yan¹, Xue-Yan Chen¹, Si-Qi Chen¹, Jia-Qi Chen², Xiao-Yong Man³; Chinese Psoriasis Real World Evidence Research Group (CPRWERG)¹

Affiliations

¹ Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
² Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: fatina@zju.edu.cn.
³ Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: manxy@zju.edu.cn.

PMID: 33964329
DOI: 10.1016/j.jaad.2021.04.093

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized
Dermatologic Agents* / adverse effects
Humans
Prospective Studies
Psoriasis* / diagnosis
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Dermatologic Agents
ixekizumab